APEX1 and non-small cell lung carcinoma: Pre-treatment APEX1 levels correlate with the clinical outcomes of patients with advanced NSCLC treated with immune checkpoint inhibitors (ICIs) monotherapy and combination therapy, and patients with higher pre-treatment APEX1 levels had shorter PFS times, both with ICIs monotherapy and combination therapy (Hu et al., 2023).